Literature DB >> 9434598

Inhibition of eukaryote protein kinases by isoquinoline and oxazine alkaloids.

B H Wang1, Z X Lu, G M Polya.   

Abstract

The aporphine isoquinoline alkaloid apomorphine is a potent inhibitor of the catalytic subunit (cAK) of rat liver cyclic AMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and Ca(2+)- and phospholipid-dependent protein kinase C (PKC) (IC50 values 1, 11, and 8 microM, respectively). However, a number of O-methylated analogues of apomorphine are inactive or poor inhibitors of cAK. The benzophenanthridine isoquinoline alkaloid sanguinarine is a potent inhibitor of cAK but is a relatively poor inhibitor of PKC (IC50 values 6 and 217 microM respectively). However a number of methylated analogues of sanguinarine are inactive as cAK inhibitors. The aporphine isoquinoline alkaloids (+)-boldine and bulbocapnine are non-competitive inhibitors of MLCK with respect to both peptide substrate and ATP. The inhibition of cAK, MLCK, and PKC by apomorphine and sanguinarine is competitive with respect to ATP as substrate. The oxazine alkaloids darrow red, nile blue A, and oxazine 170 are variously effective as inhibitors of cAK, MLCK, PKC, and CDPK (IC50 values 4-65 microM). Ca2+ binds to apomorphine and (+)-boldine which, together with nile blue A and oxazine 170, are potent inhibitors of calmodulin (CaM)-dependent MLCK (IC50 values 11, 12, 4, and 7 microM, respectively), and interact with dansyl-CaM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434598     DOI: 10.1055/s-2006-957749

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  7 in total

Review 1.  Chemical biology of histone acetyltransferase natural compounds modulators.

Authors:  Fabrizio Dal Piaz; Antonio Vassallo; Osmany Cuesta Rubio; Sabrina Castellano; Gianluca Sbardella; Nunziatina De Tommasi
Journal:  Mol Divers       Date:  2011-01-01       Impact factor: 2.943

Review 2.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

3.  Effect of chelerythrine against endotoxic shock in mice and its modulation of inflammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway.

Authors:  Weifeng Li; Ting Fan; Yanmin Zhang; Xiaofeng Niu; Wei Xing
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

4.  Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

Authors:  R Maggio; M Armogida; M Scarselli; F Salvadori; B Longoni; C Pardini; A Chiarenza; S Chiacchio; F Vaglini; R Bernardini; A Colzi; G U Corsini
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

5.  Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor.

Authors:  Anne N Shemon; Ronald Sluyter; Arthur D Conigrave; James S Wiley
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

6.  Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine.

Authors:  Jon Holy; Genelle Lamont; Edward Perkins
Journal:  BMC Cell Biol       Date:  2006-03-02       Impact factor: 4.241

7.  Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development.

Authors:  Navasona Krishnan; Christopher A Bonham; Ioana A Rus; Om Kumar Shrestha; Carla M Gauss; Aftabul Haque; Ante Tocilj; Leemor Joshua-Tor; Nicholas K Tonks
Journal:  Nat Commun       Date:  2018-01-18       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.